Ovarian Adnexal Mass

Aspira announces commercial launch of blood-based ovarian cancer risk assay

By LabPulse.com staff writers

OvaWatch uses a proprietary algorithm and seven biomarkers, combined with individual risk factors such as menopause status, to assess risk of malignancy, with a negative predictive value of 99%.

November 30, 2022

Aspira Women's Health, BioReference to distribute blood tests to detect the risk of ovarian malignancy

By LabPulse.com staff writers

The firms will co-market and distribute Aspira's Ova1Plus, which combines its Ova1 and Overa blood tests to detect the risk of ovarian malignancy in women with adnexal masses prior to surgery.

October 5, 2022

Aspira promotes OvaWatch clinical trial results

By LabPulse.com staff writers

The study highlights OvaWatch's potential for accurately assessing the risk of ovarian malignancy in patients with pelvic masses, according to Aspira.

June 16, 2022